1,500
Participants
Start Date
May 1, 2025
Primary Completion Date
May 1, 2026
Study Completion Date
December 31, 2026
Evaluate the diagnostic performance of EPIPROBE TAGMe DNA Methylation Detection Kit for Urothelial Cancer
The study aims to evaluate the diagnostic performance of the EPIPROBE TAGMe DNA Methylation Detection Kit for the detection of urothelial cancer. This assay utilizes targeted DNA methylation analysis to identify specific epigenetic alterations associated with urothelial malignancies. The performance of the kit will be assessed in terms of sensitivity, specificity, and overall diagnostic accuracy using clinical urine samples from a patient population with hematuria.
Changhai Hospital
OTHER
RenJi Hospital
OTHER
Tongji Hospital
OTHER
First Hospital of China Medical University
OTHER
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
OTHER
Shanghai Epiprobe Biotechnology Co., Ltd.
INDUSTRY